A key focus is placed on distinct pathophysiological features of molecular glioma subtypes, including alterations driven by isocitrate dehydrogenase (IDH) mutations, dysregulation of the mammalian target of rapamycin (mTOR) pathway, glutamatergic imbalance and the emerging field of cancer neuroscience. This evidence concerns the gene IDH1 and central nervous system cancer.